Elevance Health Inc (ELV)
Fair ValueFondamentale
71
Prezzo
$388.82
Capitalizzazione
$85.57B
Parte 1 · Quanto vale l'azienda
Panoramica
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Generato il 18 settembre 2026 con claude-haiku-4-5 — condiviso con tutti gli utenti
È il maggiore assicuratore sanitario americano: si contende con Elevance le stesse convenzioni aziendali, gli iscritti Medicare Advantage e gli appalti Medicaid dei singoli Stati, affiancando all'assicurazione i servizi sanitari come Elevance fa con Carelon.
Con Aetna vende polizze aziendali, Medicare Advantage e Medicaid negli stessi Stati di Elevance, e con la sua gestione dei farmaci si contende la stessa spesa farmaceutica.
È il primo operatore Medicaid del paese e il rivale principale di Elevance nelle gare indette dagli Stati e sui mercati individuali dell'Affordable Care Act.
Le due società si contendono i grandi clienti aziendali con sedi in più Stati, il segmento in cui Elevance gioca la carta della rete Blue Cross Blue Shield.
È concentrata su Medicare Advantage e punta agli stessi iscritti over 65 che Elevance considera la sua area di crescita più rapida.
Vive quasi solo di programmi pubblici e si presenta alle stesse gare statali di Elevance per Medicaid e per gli assistiti con doppia copertura.
Stato Patrimoniale e Liquidità
Ricavi
$199.13B
Esercizio chiuso il 31/12/2025
Utile Netto
$5.66B
Esercizio chiuso il 31/12/2025
Free Cash Flow
$3.17B
Patrimonio Netto Totale
$43.88B
Passività Totali
$77.47B
Rapporto di Liquidità
1.52
Copertura Interessi
5.13
Debito/EBITDA
3.55
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$497.22
Prezzo Attuale
$388.82
Margine di Sicurezza
+21.8%
Range Fair Value
$323.19 - $671.25
Intervallo di dispersione tra i metodi di valutazione usati, non una stima statisticamente calibrata.
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
15.65
ROE
12.9%
Rapporto P/B
1.88
P/FCF
13.41
Margine Lordo
89.4%
ROIC
7.1%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
7.1%
WACC
6.9%
ROIC − WACC
+0.2 pp
Il ROIC è in linea con il costo del capitale: l'azienda copre a malapena il costo del capitale.
Criteri di Analisi Fondamentale
Superati (21)
- EPS shows upward trend
- EPS CAGR 8.76%
- Price CAGR 11.28%
- ROIC 7.1%
- Gross Margin 89.4%
- P/FCF 13.41
- P/B Ratio 1.88
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 11.2%
- Revenue Growth 5Y 10.3%
- Analyst Consensus 66% Buy
- Earnings Surprise avg 15.4%
- Earnings Quality (OCF/NI) 0.76
- Share Dilution -3.6%
- Piotroski F-Score 7/9
Non superati (5)
- Operating Margin 3.6%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 2.47
Non disponibili (2)
- Dividend Payout NaN%
- Net Margin Trend (invalid data)
Piotroski F-Score
Salute finanziaria forte
Qualità degli Utili
Moderata: qualche divario tra profitti e cash
Diluizione Azionaria
Riacquisto azioni. Favorevole agli azionisti
Partecipazioni istituzionali
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Ms. Gail Koziara Boudreaux | President, CEO & Director | 64 |
| Mr. Mark Bradley Kaye | Executive VP & CFO | 45 |
| Mr. Peter David Haytaian Esq. | Special Advisor | 55 |
| Mr. Charles Morgan Kendrick Jr. | EVP and President of Commercial & Specialty Health Benefits | 59 |
| Ms. Felicia Farr Norwood | Executive VP & Chief Health Benefits Officer | 65 |
| Mr. Scott Wayne Anglin | SVP, Treasurer & Chief Investment Officer | - |
| Mr. Ronald William Penczek | Senior VP, Controller & Chief Accounting Officer | 60 |
| Mr. Nathan Allen Rich | Vice President of Investor Relations | - |
| Ms. Erin M. Wessling | Executive VP & Chief Legal Officer | 47 |
| Ms. Julie Goon | Senior Vice President of Public Affairs | - |
Rischio Audit
1
Rischio CdA
1
Rischio Compensi
2
Rischio Diritti Azionisti
6
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Documenti
- Vedi documento
Relazione annuale (10-K)
Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.
Depositato il 2026-02-06
- Vedi documento
Relazione trimestrale (10-Q)
Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.
Depositato il 2026-07-15
- Vedi documento
Comunicazione price-sensitive (8-K)
Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.
Depositato il 2026-09-10
via SEC EDGAR
Storico Ricavi
via SEC EDGAR
Ultime Notizie
Ultime notizie per ELV, da Markets Gazette.
- 4/22/2026POSITIVEElevance Health Earnings And Guidance Hike Offset Cost Concerns
Elevance Health exceeded first-quarter earnings expectations, reporting $6.05 per share against a consensus of $5.70, a 6.1% beat. The company also raised its full-year 2026 outlook, projecting adjusted earnings per share between $18.40 and $18.80, up from the previous guidance of $18.20 to $18.60. This upward revision, coupled with steady revenue growth, suggests strong operational performance. However, investors should note the company flagged increased cost pressures in its Medicaid business and a significant accrual related to CMS rates, which could impact future profitability.
- 4/7/2026POSITIVEElevance Health Stock Soars After 2.48% Medicare Rate Increase
Elevance Health Inc. experienced a significant surge on Tuesday following the finalization of a substantial 2.48% increase in Medicare Advantage reimbursement rates for 2027 by federal regulators. This favorable adjustment is expected to directly boost the company's revenue streams from its government-backed health insurance plans. For investors, this news signals improved profitability prospects and a more robust financial outlook for Elevance Health, potentially leading to upward price target revisions and increased institutional interest.
- 3/2/2026NEGATIVEElevance Health Stock Sinks After CMS Freezes Medicare Advantage Enrollment
Markets Gazette reports a significant decline in Elevance Health's stock value following the Centers for Medicare & Medicaid Services (CMS) decision to freeze new enrollments in its Medicare Advantage program. The CMS action stems from serious compliance concerns dating back to 2018. This halt in new admissions represents a substantial blow to Elevance Health, as the Medicare Advantage program is a critical component of its business and future growth strategy. Investors reacted sharply, driving the stock price down, reflecting uncertainty about the long-term financial impact of these restrictions and the company's reputation. The situation demands careful management from the company's leadership to restore regulatory and market confidence.
- 2/25/2026POSITIVEAfter stints at Nike and Kohl’s, Elevance Health’s CDIO pivots to using tech to bring more ‘delight’ to healthcare
Ratnakar Lavu, with significant experience at retail giants like Nike and Kohl's, is taking on the role of Chief Digital and Information Officer (CDIO) at Elevance Health. This strategic move suggests a growing emphasis on technological innovation within the healthcare sector. Lavu's goal is to infuse healthcare with the same "delight" and customer-centric approach typical of retail, leveraging technology to enhance the overall patient and user experience. For investors, the arrival of an executive with such a diverse and consumer-oriented background could signal a potential acceleration in Elevance Health's digital transformation, promising greater operational efficiency and improved customer loyalty, key drivers for future growth.
- 2/24/2026NEUTRALElevance Health Executive: Committed to Affordability
Catherine Gaffigan, president of health solutions at Elevance Health, highlighted utilization as a key driver of rising healthcare costs. Speaking on Bloomberg's The Close, she elaborated that an aging population, coupled with higher pharmaceutical and hospital expenses, significantly contributes to this trend. These insights provide investors with an internal perspective on the structural challenges facing the healthcare sector. While Elevance Health is committed to affordability, the discussion around cost drivers underscores the complexity of the current landscape and the long-term pressures on healthcare providers and insurers. For investors, understanding these factors is crucial for assessing the sustainability of business models within the industry.
via Markets Gazette